# 908 Devices Inc.: financial statements, quarterly

MASS · Nasdaq · CIK 1555279 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/mass.md) · [Financials](/companies/mass/financials.md) · [Filings](/companies/mass/filings.md) · [Insiders](/companies/mass/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/mass/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [14.3](/filings/0001558370-24-015175.md) | [14.4 d](/filings/0001558370-25-002459.md) | [7.4](/filings/0001558370-25-007502.md) | [11.5](/filings/0001558370-25-010189.md) | [14.5](/filings/0001104659-25-108875.md) | [14.3 d](/filings/0001104659-26-024877.md) | [11.8](/filings/0001104659-26-055917.md) | [13.0](/filings/0001104659-26-093731.md) | [14.0](/filings/0001104659-25-108875.md) | [17.4 d](/filings/0001104659-26-024877.md) | [13.4](/filings/0001104659-26-055917.md) | [16.1](/filings/0001104659-26-093731.md) |
| Cost of revenue | $m | [6.4](/filings/0001558370-24-015175.md) | [7.1 d](/filings/0001558370-25-002459.md) | [3.5](/filings/0001558370-25-007502.md) | [5.3](/filings/0001558370-25-010189.md) | [6.7](/filings/0001104659-25-108875.md) | [7.7 d](/filings/0001104659-26-024877.md) | [6.2](/filings/0001104659-26-055917.md) | [6.7](/filings/0001104659-26-093731.md) | [6.7](/filings/0001104659-25-108875.md) | [8.2 d](/filings/0001104659-26-024877.md) | [6.5](/filings/0001104659-26-055917.md) | [7.7](/filings/0001104659-26-093731.md) |
| Gross profit | $m | [7.9](/filings/0001558370-24-015175.md) | [7.3 d](/filings/0001558370-25-002459.md) | [3.9](/filings/0001558370-25-007502.md) | [6.2](/filings/0001558370-25-010189.md) | [7.8](/filings/0001104659-25-108875.md) | [6.7 d](/filings/0001104659-26-024877.md) | [5.5](/filings/0001104659-26-055917.md) | [6.4](/filings/0001104659-26-093731.md) | [7.4](/filings/0001104659-25-108875.md) | [9.2 d](/filings/0001104659-26-024877.md) | [6.9](/filings/0001104659-26-055917.md) | [8.3](/filings/0001104659-26-093731.md) |
| Research and development | $m | [5.5](/filings/0001558370-24-015175.md) | [5.4 d](/filings/0001558370-25-002459.md) | [3.3](/filings/0001558370-25-007502.md) | [3.6](/filings/0001558370-25-010189.md) | [4.2](/filings/0001104659-25-108875.md) | [3.9 d](/filings/0001104659-26-024877.md) | [3.8](/filings/0001104659-26-055917.md) | [4.4](/filings/0001104659-26-093731.md) | [3.8](/filings/0001104659-25-108875.md) | [3.5 d](/filings/0001104659-26-024877.md) | [3.5](/filings/0001104659-26-055917.md) | [3.6](/filings/0001104659-26-093731.md) |
| Selling, general and administrative | $m | [11.3](/filings/0001558370-24-015175.md) | [11.8 d](/filings/0001558370-25-002459.md) | [8.2](/filings/0001558370-25-007502.md) | [11.1](/filings/0001558370-25-010189.md) | [9.7](/filings/0001104659-25-108875.md) | [10.5 d](/filings/0001104659-26-024877.md) | [10.2](/filings/0001104659-26-055917.md) | [10.3](/filings/0001104659-26-093731.md) | [9.1](/filings/0001104659-25-108875.md) | [8.8 d](/filings/0001104659-26-024877.md) | [9.9](/filings/0001104659-26-055917.md) | [11.1](/filings/0001104659-26-093731.md) |
| Operating income | $m | [(9.1)](/filings/0001558370-24-015175.md) | [(9.7) d](/filings/0001558370-25-002459.md) | [(7.6)](/filings/0001558370-25-007502.md) | [(8.5)](/filings/0001558370-25-010189.md) | [(24.5)](/filings/0001104659-25-108875.md) | [(16.7) d](/filings/0001104659-26-024877.md) | [(11.0)](/filings/0001104659-26-055917.md) | [(15.2)](/filings/0001104659-26-093731.md) | [(16.3)](/filings/0001104659-25-108875.md) | [3.1 d](/filings/0001104659-26-024877.md) | [(12.9)](/filings/0001104659-26-055917.md) | [(12.8)](/filings/0001104659-26-093731.md) |
| Interest expense | $m | [(0.4)](/filings/0001558370-23-017879.md) | [0.0 d](/filings/0001558370-24-002818.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.1)](/filings/0001558370-24-015175.md) | [(0.0) d](/filings/0001558370-25-002459.md) | [(0.1)](/filings/0001558370-24-006601.md) | [(0.1)](/filings/0001558370-24-010969.md) | [(0.1)](/filings/0001558370-24-015175.md) | [(0.1) d](/filings/0001558370-25-002459.md) | not reported | [0.1](/filings/0001104659-26-093731.md) | [0.0](/filings/0001104659-25-108875.md) | [(0.2) d](/filings/0001104659-26-024877.md) | not reported | [(0.1)](/filings/0001104659-26-093731.md) |
| Net income | $m | [(7.1)](/filings/0001558370-24-015175.md) | [(7.4) d](/filings/0001558370-25-002459.md) | [(10.9)](/filings/0001104659-25-108875.md) | [(12.5)](/filings/0001104659-25-108875.md) | [(29.3)](/filings/0001104659-25-108875.md) | [(19.4) d](/filings/0001104659-26-024877.md) | [43.6](/filings/0001104659-26-093731.md) | [(13.3)](/filings/0001104659-26-093731.md) | [(15.0)](/filings/0001104659-25-108875.md) | [4.2 d](/filings/0001104659-26-024877.md) | [(12.0)](/filings/0001104659-26-093731.md) | [(11.9)](/filings/0001104659-26-093731.md) |
| Diluted EPS | $ per share | [(0.22)](/filings/0001558370-24-015175.md) | not reported | [(0.33)](/filings/0001558370-25-007502.md) | [(0.37)](/filings/0001558370-25-010189.md) | [(0.84)](/filings/0001104659-25-108875.md) | not reported | [1.23](/filings/0001104659-26-055917.md) | [(0.37)](/filings/0001104659-26-093731.md) | [(0.41)](/filings/0001104659-25-108875.md) | not reported | [(0.32)](/filings/0001104659-26-055917.md) | [(0.32)](/filings/0001104659-26-093731.md) |
| Basic EPS | $ per share | [(0.22)](/filings/0001558370-24-015175.md) | not reported | [(0.33)](/filings/0001558370-25-007502.md) | [(0.37)](/filings/0001558370-25-010189.md) | [(0.84)](/filings/0001104659-25-108875.md) | not reported | [1.23](/filings/0001104659-26-055917.md) | [(0.37)](/filings/0001104659-26-093731.md) | [(0.41)](/filings/0001104659-25-108875.md) | not reported | [(0.32)](/filings/0001104659-26-055917.md) | [(0.32)](/filings/0001104659-26-093731.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [118](/filings/0001558370-24-015175.md) | [121](/filings/0001558370-25-002459.md) | [105](/filings/0001558370-25-007502.md) | [46.8](/filings/0001558370-25-010189.md) | [45.0](/filings/0001104659-25-108875.md) | [44.0](/filings/0001104659-26-024877.md) | [79.2](/filings/0001104659-26-055917.md) | [61.8](/filings/0001104659-26-093731.md) | [62.8](/filings/0001104659-25-108875.md) | [70.5](/filings/0001104659-26-093731.md) | [67.6](/filings/0001104659-26-055917.md) | [63.0](/filings/0001104659-26-093731.md) |
| Current assets | $m | [180](/filings/0001558370-23-017879.md) | [174](/filings/0001558370-25-002459.md) | [162](/filings/0001558370-24-006601.md) | [110](/filings/0001558370-24-010969.md) | [109](/filings/0001558370-24-015175.md) | [103](/filings/0001104659-26-024877.md) | [149](/filings/0001558370-25-007502.md) | [148](/filings/0001558370-25-010189.md) | [145](/filings/0001104659-25-108875.md) | [145](/filings/0001104659-26-093731.md) | [142](/filings/0001104659-26-055917.md) | [132](/filings/0001104659-26-093731.md) |
| Total assets | $m | [208](/filings/0001558370-23-017879.md) | [203](/filings/0001558370-25-002459.md) | [190](/filings/0001558370-24-006601.md) | [209](/filings/0001558370-24-010969.md) | [178](/filings/0001558370-24-015175.md) | [159](/filings/0001104659-26-024877.md) | [196](/filings/0001558370-25-007502.md) | [192](/filings/0001558370-25-010189.md) | [191](/filings/0001104659-25-108875.md) | [190](/filings/0001104659-26-093731.md) | [187](/filings/0001104659-26-055917.md) | [198](/filings/0001104659-26-093731.md) |
| Current liabilities | $m | [22.3](/filings/0001558370-23-017879.md) | [22.5](/filings/0001558370-25-002459.md) | [19.3](/filings/0001558370-24-006601.md) | [21.7](/filings/0001558370-24-010969.md) | [25.7](/filings/0001558370-24-015175.md) | [25.1](/filings/0001104659-26-024877.md) | [19.6](/filings/0001558370-25-007502.md) | [29.7](/filings/0001558370-25-010189.md) | [41.5](/filings/0001104659-25-108875.md) | [34.1](/filings/0001104659-26-093731.md) | [39.7](/filings/0001104659-26-055917.md) | [49.4](/filings/0001104659-26-093731.md) |
| Total liabilities | $m | [38.5](/filings/0001558370-23-017879.md) | [37.5](/filings/0001558370-25-002459.md) | [32.9](/filings/0001558370-24-006601.md) | [52.4](/filings/0001558370-24-010969.md) | [47.2](/filings/0001558370-24-015175.md) | [44.9](/filings/0001104659-26-024877.md) | [36.6](/filings/0001558370-25-007502.md) | [42.9](/filings/0001558370-25-010189.md) | [54.6](/filings/0001104659-25-108875.md) | [46.4](/filings/0001104659-26-093731.md) | [52.5](/filings/0001104659-26-055917.md) | [70.8](/filings/0001104659-26-093731.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [170](/filings/0001558370-24-015175.md) | [165](/filings/0001104659-26-024877.md) | [157](/filings/0001104659-25-108875.md) | [156](/filings/0001104659-25-108875.md) | [131](/filings/0001104659-25-108875.md) | [115](/filings/0001104659-26-093731.md) | [159](/filings/0001104659-26-093731.md) | [149](/filings/0001104659-26-093731.md) | [136](/filings/0001104659-25-108875.md) | [144](/filings/0001104659-26-093731.md) | [134](/filings/0001104659-26-093731.md) | [127](/filings/0001104659-26-093731.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(4.6) d](/filings/0001558370-24-015175.md) | [(1.9) d](/filings/0001558370-25-002459.md) | [(9.4)](/filings/0001558370-25-007502.md) | [(13.0) d](/filings/0001558370-25-010189.md) | [(5.6) d](/filings/0001104659-25-108875.md) | [(2.2) d](/filings/0001104659-26-024877.md) | [(15.0)](/filings/0001104659-26-055917.md) | [(5.8) d](/filings/0001104659-26-093731.md) | [(4.2) d](/filings/0001104659-25-108875.md) | [1.3 d](/filings/0001104659-26-024877.md) | [1.2](/filings/0001104659-26-055917.md) | [3.2 d](/filings/0001104659-26-093731.md) |
| Capital expenditure | $m | [0.2 d](/filings/0001558370-24-015175.md) | [0.3 d](/filings/0001558370-25-002459.md) | [0.9](/filings/0001558370-25-007502.md) | [(0.6) d](/filings/0001558370-25-010189.md) | [0.2 d](/filings/0001104659-25-108875.md) | [0.2 d](/filings/0001104659-26-024877.md) | [0.2](/filings/0001104659-26-055917.md) | [0.1 d](/filings/0001104659-26-093731.md) | [0.7 d](/filings/0001104659-25-108875.md) | [(0.0) d](/filings/0001104659-26-024877.md) | [0.0](/filings/0001104659-26-055917.md) | [0.2 d](/filings/0001104659-26-093731.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [31.6](/filings/0001558370-23-017879.md) | [32.0](/filings/0001558370-24-006601.md) | [32.2](/filings/0001558370-24-010969.md) | [32.3](/filings/0001558370-24-015175.md) | [32.7](/filings/0001558370-25-007502.md) | [34.1](/filings/0001558370-25-010189.md) | [34.7](/filings/0001104659-25-108875.md) | [35.4](/filings/0001104659-26-055917.md) | [35.9](/filings/0001104659-26-093731.md) | [36.1](/filings/0001104659-25-108875.md) | [36.8](/filings/0001104659-26-055917.md) | [37.7](/filings/0001104659-26-093731.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,333,705 at 2026-08-07, from the cover of the [10-Q filed 2026-08-11](/filings/0001104659-26-093731.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.